Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

TRASTUZUMAB DERUXTECAN for Neoplasm: Side Effects & Safety Data

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

There are 43 adverse event reports in the FDA FAERS database where TRASTUZUMAB DERUXTECAN was used for Neoplasm.

Most Reported Side Effects for TRASTUZUMAB DERUXTECAN

Side Effect Reports % Deaths Hosp.
Death 384 14.3% 384 24
Off label use 258 9.6% 36 71
Nausea 251 9.4% 18 86
Myelosuppression 242 9.0% 0 98
Fatigue 186 6.9% 14 61
Malignant neoplasm progression 171 6.4% 48 29
Vomiting 140 5.2% 20 58
Diarrhoea 132 4.9% 23 68
Interstitial lung disease 130 4.8% 46 46
Pneumonitis 125 4.7% 41 48
Metastases to central nervous system 103 3.8% 22 25
Toxicity to various agents 97 3.6% 2 15
Asthenia 95 3.5% 13 40
Disease progression 87 3.2% 29 14
Dyspnoea 77 2.9% 23 38

Other Indications for TRASTUZUMAB DERUXTECAN

Her2 positive breast cancer (768) Breast cancer metastatic (503) Breast cancer (378) Product used for unknown indication (362) Her2 low breast cancer (110) Breast cancer female (78) Her2 negative breast cancer (57) Chemotherapy (48) Gastric cancer (37) Invasive ductal breast carcinoma (24)

Other Drugs Used for Neoplasm

BEVACIZUMAB (502) ATEZOLIZUMAB (404) CYCLOPHOSPHAMIDE (385) CARBOPLATIN (283) PACLITAXEL (267) NIVOLUMAB (219) OXALIPLATIN (185) PEMBROLIZUMAB (173) LENALIDOMIDE (171) DOXORUBICIN (150)

Related Pages

TRASTUZUMAB DERUXTECAN Full Profile All Neoplasm Drugs TRASTUZUMAB DERUXTECAN Demographics TRASTUZUMAB DERUXTECAN Timeline